Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Recruiting · NCT06387056 · Registry updated 2024-04-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) | Locally Advanced Prostate Cancer; Oligometastatic Prostate Cancer | Recruiting | Phase 2 | 2024-04-26 | NCT06387056 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First Affiliated Hospital of Xiamen University | 107 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of Xiamen University | Xiamen | China | 25 |